Eucomed challenges "irrational" national decisions:
This article was originally published in Clinica
Executive Summary
Six issues that have been identified as priorities by the Eucomed Legal Issues Group for 2005 include challenging irrational national reimbursement decisions as well as continuing scrutiny and understanding of national procurement practices. These reflect the mounting obstacles that industry still faces despite regulatory convergence. The other four issues are: late payments and what can be learnt from the Spanish and Italian approaches; new technologies - the need for appropriate regulatory mechanisms to avoid the inevitable drift towards inappropriate and expensive pharma-based systems; strategic future of regulation - reform of the Medical Devices Directive and related legislation; and analysis of the implications of EU horizontal measures.
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.